Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

eas of pediatric infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at www.medimmune.com.

Forward Looking Statements

This announcement may contain, in addition to historical information, certain forward-looking statements regarding motavizumab, an investigational MAb, which involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in MedImmune's filings with the U.S. Securities and Exchange Commission. The company is developing motavizumab for potential future marketing. There can be no assurance that such development efforts will succeed, that motavizumab will receive required regulatory approval or that, even if such regulatory approval is received, that motavizumab would ultimately achieve commercial success.

Notice to Investors and Stockholders of MedImmune

This release is neither an offer to purchase nor a solicitation of an offer to sell shares of MedImmune. MedImmune stockholders are urged to read the relevant tender offer documents from AstraZeneca PLC which have been filed on May 3, 2007 because they will contain important information that stockholders should consider before making any decision regarding tendering their shares. AstraZeneca has filed tender offer materials with the U.S. Securities and Exchange Commission, and MedImmune has also filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. The tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement contain important informat
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:5/26/2015)... , May 27, 2015 /CNW/ - Export Development Canada (EDC) ... financing for Montreal,s Valeant Pharmaceuticals ... multinational pharmaceutical company. The loan is ... facility that Valeant is using to fund the repayment ... a leading gastrointestinal pharmaceutical company based in the US. ...
(Date:5/26/2015)...  The National Association of Boards of Pharmacy ® ... general availability for the .pharmacy domain begins June 3, ... may apply for .pharmacy domain names. The ... NABP has approved more than 300 .pharmacy domain names ... NABP created the .pharmacy TLD to provide consumers worldwide ...
(Date:5/26/2015)... 2015  AbbVie (NYSE: ABBV ) presented ... of its investigational, all-oral, interferon (IFN)- and ribavirin ... the Annual Meeting of the Japan Society of ... 1 GIFT-I evaluated genotype 1b (GT1b) chronic ... and without cirrhosis, who were either treatment-naïve or ...
Breaking Medicine Technology:EDC provides Valeant Pharmaceuticals with USD 67.5 M to support recent Salix Pharmaceuticals acquisition 2General Availability for .Pharmacy Domain Names Begins June 3, 2015 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 3AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 4AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 5AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 6
... ANGELES , Aug. 5 B. Braun Medical Inc. (B. Braun) ... gain premier access to customized, evidence-based drug libraries provided by the Zynx Health ... , , , ... , , , ...
... Aug. 5 Decision Resources, one of the ... healthcare issues, finds that, in first- and second-line treatment ... nearly 70 percent of surveyed infectious disease specialists and ... use Medarex/Merck,s CDA1 and CDB1, one year after the ...
Cached Medicine Technology:B. Braun Customers Gain Premier Access to Zynx Health Device Network's Evidence-based, Customizable Drug Library Program 2B. Braun Customers Gain Premier Access to Zynx Health Device Network's Evidence-based, Customizable Drug Library Program 3B. Braun Customers Gain Premier Access to Zynx Health Device Network's Evidence-based, Customizable Drug Library Program 4B. Braun Customers Gain Premier Access to Zynx Health Device Network's Evidence-based, Customizable Drug Library Program 5B. Braun Customers Gain Premier Access to Zynx Health Device Network's Evidence-based, Customizable Drug Library Program 6In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1 2In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1 3
(Date:5/26/2015)... Francisco, CA (PRWEB) May 27, 2015 ... and beautiful technology for women, today announces the ... that monitors women’s stress, sleep, activity and ovulation. ... jewelry with innovative health tracking technolo- gy, particularly ... stress levels, to provide women with lifestyle data ...
(Date:5/26/2015)... BROOK, Ill. (PRWEB) May 26, 2015 ... be an early marker of specific types of Alzheimer’s ... a new study published in the journal Radiology. ... Agosta, M.D., Ph.D., co-author of the study conducted at ... Milan, Italy. “However, white matter damage has a central ...
(Date:5/26/2015)... May 27, 2015 Visiting Nurse Association of ... at the American Cancer Society’s annual Relay for Life fundraiser. ... 12:00AM at Mennen Sports Arena, 161 East Hanover Ave, Morristown, ... the track to raise money and awareness to help the ... , According to the ACS, it is estimated that more ...
(Date:5/26/2015)... 2015 Securityhunter has been ... the United States Department of Health and Human Services ... The MATOC was awarded through the General Services Administration ... the PSC, which is a fee-for-service agency. The award ... options, and is an enterprise–wide physical security and security ...
(Date:5/26/2015)... ANGELES (PRWEB) May 27, 2015 Readers ... processes may find help in author Chester Litvin ... Psychoconduction : Litvin’s Code” (published by Trafford Publishing). , ... new approach for stimulating the brain. This book will ... to reeducate their sensory brain cells . He ...
Breaking Medicine News(10 mins):Health News:Bellabeat debuts the LEAF - smart jewelry that monitors women’s health. 2Health News:Bellabeat debuts the LEAF - smart jewelry that monitors women’s health. 3Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 2Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 3Health News:North Jersey Home Care Agency Supports Relay for Life Fundraiser 2Health News:Securityhunter Has Been Awarded a Multiple Award Task Order Contract (MATOC) by the Department of Health and Human Services 2Health News:Chester Litvin’s New Book Offers ‘Tune-Up’ for Brain Cells 2Health News:Chester Litvin’s New Book Offers ‘Tune-Up’ for Brain Cells 3
... , FRIDAY, Jan. 22 (HealthDay News) -- If you,re ready to ... potty training may be between the second and third birthdays. , ... window for moving your child out of diapers. Children who were ... incontinence -- daytime wetting and bed-wetting -- between ages 4 and ...
... physical and mental benefits as people grow old , FRIDAY, ... and gunning down bad guys might not sound like things ... , But they might want to start, some experts on ... have the potential to help seniors age more gracefully, keeping ...
... Drug Administration has approved the drug fampridine-SR for the treatment ... Medical Center (URMC) have been evaluating the effects of the ... the first medication shown to enhance some neurological functions in ... the way for today,s action by the FDA. ...
... Society report outlines 21 challenges and needs for global tobacco ... and expertise needed to reduce the rising tide of tobacco ... are the target of the multinational tobacco industry. The report ... issue of CA: A Cancer Journal for Clinicians . ...
... most women, having a baby is a joyful experience. But ... by grief, anxiety and depression. Global figures suggest that between ... first time are struck by depression. For the second birth, ... Kristin Akerjordet at the University of Stavanger in Norway, surveyed ...
... 2010) -- Weill Cornell Medical College has established a ... diverse and medically underserved communities in New York City. ... and Community Engagement (CEDREC) was created through an $8 ... and Health Disparities (NCMHD), a division of the National ...
Cached Medicine News:Health News: Potty Training Best Between Ages 2 and 3 2Health News: Potty Training Best Between Ages 2 and 3 3Health News: Potty Training Best Between Ages 2 and 3 4Health News:Video Gaming Just Might Fight Aging 2Health News:Video Gaming Just Might Fight Aging 3Health News:Researchers welcome new multiple sclerosis drug 2Health News:Researchers welcome new multiple sclerosis drug 3Health News:Global tobacco report outlines 21 challenges for 21st century 2Health News:Global tobacco report outlines 21 challenges for 21st century 3Health News:Emotions should be taken seriously 2Health News:Emotions should be taken seriously 3Health News:National Center on Minority Health and Health Disparities awards $8 million to Weill Cornell 2
... data for future generations. Most gels can be ... plate of our gel dryer, covering them with ... them to hold the cellophane flat. Tut's Tombs ... an open area somewhat larger than the gel ...
... Most gels can be dried by positioning them ... dryer, covering them with wet semi-permeable cellophane and ... cellophane flat. Tut's Tombs also produce great fluorographs. ... larger than the gel to be dried. Note ...
... Hoefer SE 1200 Easy Breeze Air Gel ... 25 cm or 24 gels 8 ... warm air temperatures for rapid drying, or no ... photograph or store smooth, transparent, dried gels. Add ...
... Gel Dryer : Dry up to 6 gels ... 10 cm without a vacuum pump. Choose ... no heat for controlled drying of problem gels. ... Add and remove gels at any time without ...
Medicine Products: